Loading clinical trials...
Loading clinical trials...
In this pilot study, the investigators will test the hypothesis that patients with postural tachycardia syndrome will have an elevated percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS. The investigators further hypothesize that the percentage of POTS patients with antibodies will be higher in those patients with a viral infection at the onset of their illness than in those patients with other or undefined illness onsets.
Postural orthostatic tachycardia syndrome is poorly understood. Many of these patients have elevated levels of plasma norepinephrine, particularly when upright One subgroup of patients has a primary hyperadrenergic state. The majority of patients have a marked deficit in plasma blood volume compared to healthy control subjects. The investigators have previously reported that some patients suffer paradoxically from a partial dysautonomia affecting the lower limbs. Most patients seem to suffer from either a primary or secondary increase in central sympathetic nervous system drive. Recent data have shown that patients with postural orthostatic tachycardia syndrome have a lower cardiac stroke volume than their healthy counterparts and this low stroke volume may drive their orthostatic tachycardia. The investigators plan to do the following: The physical examination will include (at minimum): * Height * Weight * Orthostatic vital signs (heart rate and blood pressure) Supine and Standing for up to 10 minutes * Beighton Criteria for Joint Hypermobility Syndrome (Ehlers-Danlos III) * Dependent acrocyanosis (during stand test) Continuous Heart Rate and Blood Pressure Recording A subset of subjects will be given the opportunity to also have continuous recordings of heart rate and blood pressure for 5-10 minutes while lying down quietly. They will be instrumented with EKG patches on their body and a finger blood pressure cuff, and these data will be digitally sampled and acquired on a dedicated laptop computer for later offline analysis. There will be an optional rider on the consent form to allow the patient to consent to this portion of the study. Blood work Blood will be drawn for future assay and analysis of the following tests: * Antibodies regulating cardiovascular function o The clinical significance of these antibodies is unknown. The investigators will share the results of the antibody panel with the subject, but with the caveat that no clinical interpretation or comment on significance can be made. * Inflammatory markers The total amount of blood drawn for this project will be less than 15 ml. Questionnaires * RAND-36 * Health Thermometer * Chandler Fatigue Scale * Daily diary of Fatigue Symptoms - Fibromyalgia * Pain Detect Questionnaire * Orthostatic Grading Scale * COMPASS-31 * Structured History (including some of the elements from section 6.1) These questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.
Age
13 - 80 years
Sex
ALL
Healthy Volunteers
Yes
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Start Date
July 1, 2014
Primary Completion Date
July 1, 2029
Completion Date
July 1, 2029
Last Updated
October 10, 2025
212
ACTUAL participants
History
OTHER
Physical
OTHER
blood draw
OTHER
Questionnaires
BEHAVIORAL
Lead Sponsor
Vanderbilt University
NCT06593600
NCT07196397
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06616363